Tildipirosin

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of tildipirosin in China. Welcome to wholesale bulk high quality tildipirosin for sale here from our factory. Good service and reasonable price are available.

Tildipirosin, a novel semisynthetic macrolide antibiotic derived from tylosin, has emerged as a critical therapeutic agent in veterinary medicine. Its broad-spectrum antimicrobial activity, combined with favorable pharmacokinetic properties, makes it particularly effective against respiratory pathogens in livestock.

It is a 16-membered macrolide antibiotic with a unique chemical structure characterized by the presence of three basic moieties: a mycaminose sugar at C5 and two piperidine rings at C20 and C23. This configuration enhances its lipophilicity and binding affinity to the bacterial ribosome. The primary mechanism of action involves binding to the 50S ribosomal subunit, inhibiting peptide chain elongation, and thereby blocking bacterial protein synthesis. Unlike earlier macrolides, it's three basic groups improve its stability in biological fluids and extend its half-life, contributing to its prolonged therapeutic effect.

Additional information of chemical compound:

Tildipirosin COA

Antimicrobial Resistance

Mechanisms of Resistance

Resistance to it primarily arises through mutations in the 23S rRNA gene, particularly in domains II and V. These mutations alter the drug's binding site, reducing its affinity for the ribosome. Additionally, the presence of efflux pumps, such as msr(E)-mph(E), can confer resistance by expelling the drug from bacterial cells. Resistance rates remain low in field isolates, but surveillance studies are essential to monitor emerging trends.

Surveillance and Stewardship

Given the importance of macrolides in veterinary medicine, prudent use of Tildipirosin is critical to preserve its efficacy. Antimicrobial stewardship programs should emphasize diagnostic testing to confirm susceptibility and limit prophylactic use to high-risk scenarios. Regular monitoring of resistance patterns through national surveillance networks can guide treatment decisions and inform policy.

Clinical Applications in Pigs

Porcine Respiratory Disease Complex (PRDC)

PRDC is a multifactorial disease caused by viral and bacterial pathogens, including A. pleuropneumoniae, P. multocida, and M. hyopneumoniae. It has demonstrated superior efficacy in treating PRDC, with cure rates exceeding 90% in clinical trials. A study comparing this(4 mg/kg IM) to tulathromycin (2.5 mg/kg SC) and tilmicosin (20 mg/kg IM) reported cure rates of 93%, 92%, and 86%, respectively. It-treated pigs also exhibited lower mortality rates and improved weight gain compared to controls.

Prevention and Control

It's long half-life and high lung concentrations make it ideal for preventive use. In pigs, a single 4 mg/kg IM dose administered 5–7 days prior to anticipated stressors (e.g., weaning, transportation) significantly reduces the incidence of respiratory disease. Its activity against M. hyopneumoniae and Haemophilus parasuis further enhances its value in PRDC management, particularly in herds with a history of endemic infections.

Clinical Applications in Cattle

Bovine Respiratory Disease (BRD)

BRD is a leading cause of morbidity and mortality in feedlot cattle, with Mannheimia haemolytica, P. multocida, and Histophilus somni as primary pathogens. This has shown efficacy in both treatment and metaphylaxis of BRD. A study evaluating its prophylactic use in calves challenged with H. somni reported a 70% reduction in lung lesions compared to untreated controls. When administered 5 days prior to challenge, Tildipirosin prevented pathogen isolation from bronchial secretions and reduced clinical disease severity.

Therapeutic Efficacy

In therapeutic trials, it(4 mg/kg IM) demonstrated cure rates comparable to tulathromycin (2.5 mg/kg SC) and tilmicosin (10 mg/kg IM) for BRD. However, its longer half-life in bovine lungs (up to 10 days) may provide prolonged protection against reinfection, reducing the need for retreatments. Additionally, it's activity against Mycoplasma bovis makes it valuable in BRD cases complicated by mycoplasmal infection.

Usage in Sheep and Goats

Respiratory Infections-This has shown promise in treating respiratory infections in small ruminants, particularly those caused by Mannheimia haemolytica and Mycoplasma ovipneumoniae. While its use in sheep and goats is less widespread than in pigs and cattle, clinical trials have reported favorable outcomes.

Dosage and Administration

The recommended dosage for sheep and goats is 4 mg/kg body weight, administered via SC injection. A single dose provides prolonged therapeutic coverage, with lung concentrations remaining elevated for up to 7 days.

Clinical Efficacy

Studies indicate that it reduces clinical signs and improves growth rates in lambs with pneumonia. Its activity against M. ovipneumoniae makes it valuable in managing enzootic pneumonia in sheep flocks, particularly in areas where the pathogen is endemic.

Clinical Applications in Small Ruminants

Respiratory Infections in Sheep and Goats

This has been explored for treating respiratory infections in small ruminants, particularly those caused by Mannheimia haemolytica and Mycoplasma ovipneumoniae. Studies indicate its efficacy in reducing clinical signs and improving growth rates in lambs with pneumonia. A single 4 mg/kg SC dose provides prolonged therapeutic coverage, with lung concentrations remaining elevated for up to 7 days.

Dermatological Conditions

It has also shown promise in treating dermatological conditions in sheep, such as contagious ovine digital dermatitis (CODD). Its activity against Treponema spp., the causative agents of CODD, suggests potential for topical or systemic use in managing this debilitating condition.

Clinical Efficacy

Novel Formulations and Delivery Systems

Research is underway to develop sustained-release formulations of this, aiming to extend its duration of action and reduce the frequency of administrations. Nanoparticle-based delivery systems may enhance its tissue penetration and bioavailability, particularly in hard-to-reach infections. Additionally, topical formulations for dermatological conditions in small ruminants could expand its clinical applications.

Combination Therapies

Combining it with other antimicrobials or immunomodulators could enhance its efficacy against resistant pathogens or mixed infections. For example, pairing it with a beta-lactam antibiotic may provide synergistic activity against P. multocida and A. pleuropneumoniae. Additionally, combining it with non-steroidal anti-inflammatory drugs (NSAIDs) could reduce inflammation and improve clinical outcomes in severe respiratory cases.

Surveillance and Resistance Management

The emergence of resistance to it, particularly through mutations in the 23S rRNA gene or the acquisition of efflux pumps, underscores the need for ongoing surveillance. National and international networks should monitor resistance patterns and guide treatment decisions. Additionally, research into alternative targets or combination therapies could help mitigate resistance development.

It represents a significant advancement in veterinary medicine, offering a potent, long-acting therapeutic option for respiratory diseases in livestock. Its unique chemical structure, favorable pharmacokinetic profile, and broad-spectrum activity make it a critical tool in managing PRDC in pigs, BRD in cattle, and respiratory infections in small ruminants. However, the emergence of resistance and the need for prudent use highlight the importance of ongoing research and surveillance. As the livestock industry continues to evolve, it will remain a vital component of animal health management, ensuring the welfare of livestock and the sustainability of food production. Future research should focus on optimizing its use, exploring novel formulations, and addressing emerging resistance challenges to sustain its efficacy for generations to come.

Tildipirosin is a semi-synthetic 16-membered ring macrolide antibiotic with unique and stable chemical properties. It has significant application value in the veterinary field. The following is a detailed description of its chemical properties:

The molecular formula of it is C41H71N3O8, with a molecular weight ranging from approximately 734 to 738 g/mol (there are slight differences among various sources, possibly due to different measurement methods or purity levels). Its core structure is a 16-membered macrocyclic lactone ring, which classifies it as a macrolide antibiotic family, similar in structure to teicoplanin and teramycin. The ring is modified with multiple functional groups, including three nitrogen atoms (giving the molecule trisulfuric properties) as well as hydroxyl groups, ether bonds, etc. These groups significantly enhance the stability, lipophilicity, and biological activity of the drug through chemical modification. For instance, the introduction of nitrogen atoms strengthens the binding ability of the molecule to bacterial ribosomes, while the lipophilic side chain promotes the drug's penetration and accumulation in tissues.

Physical Properties and Stability

It usually exists in liquid form at room temperature (such as 18% injection solution). It has good water solubility, making it convenient for preparing injections. Although the specific melting point, boiling point, and other data are not publicly disclosed, as a semi-synthetic antibiotic, its chemical stability has been optimized and can maintain activity during storage and use. For example, in the injection solution, the drug molecules form a stable system with the solvent molecules, avoiding degradation or precipitation. Additionally, its redox properties are stable and are not easily affected by light, temperature, or pH changes, thus ensuring the persistence of the drug efficacy.

Chemical Modification and Enhancement of Efficacy

The chemical modification of it is the key to enhancing its efficacy. By introducing specific groups onto the macrolide ring, the drug achieves precise targeting of bacterial ribosomes. Specifically, the nitrogen atom in its molecule binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and thereby blocking bacterial growth. This mechanism is similar to that of classic macrolide antibiotics such as erythromycin, but the modified structure of it enables it to remain active against certain drug-resistant bacterial strains. For example, against common pathogenic bacteria such as mycoplasma and Pasteurella, it shows a stronger inhibitory effect and is less likely to induce the development of drug resistance.

Lipophilicity and Tissue Permeability

It has excellent lipophilicity, which enables it to easily penetrate cell membranes and biological barriers, reaching high concentrations in tissues. Studies have shown that its concentration in lung tissue is significantly higher than that in plasma, and this distribution characteristic makes it an ideal drug for treating respiratory diseases (such as swine respiratory disease syndrome). Lipophilicity also promotes the accumulation of the drug in adipose tissue, prolonging the duration of action and reducing the frequency of administration. For example, after a single injection, it can maintain an effective concentration in the animal body for several days, improving the convenience and compliance of treatment.

Chemical Stability and Safety

In terms of chemical stability, it demonstrates excellent tolerance. The ether bonds and hydroxyl groups in its molecular structure are not prone to hydrolysis or oxidation reactions, ensuring the stability of the drug during storage and use. Additionally, its tris-basic property enables it to maintain activity in different pH environments, further expanding its application scope. In terms of safety, it has low toxicity and is not prone to interact with other drugs. For instance, at the recommended dose, it has no significant impact on the liver and kidney functions of animals, and no obvious allergic reactions or accumulation poisoning have been observed.

In summary, as a novel semisynthetic macrolide antibiotic developed from tylosin, it occupies an important position in modern veterinary clinical practice with its distinct structural advantages and reliable antimicrobial efficacy. Its unique 16-membered ring structure, containing mycaminose and two piperidine rings, significantly enhances lipophilicity and ribosome binding ability, laying a solid structural foundation for its potent antibacterial activity. By targeting the bacterial 50S ribosomal subunit and inhibiting protein synthesis, it exerts strong inhibitory effects on a variety of livestock respiratory pathogens. Compared with traditional macrolide antibiotics, its three basic groups greatly improve stability in vivo and prolong its half-life, thus achieving long-lasting therapeutic effects. These characteristics make it highly adaptable to the actual needs of livestock breeding, effectively controlling respiratory infections, reducing the frequency of administration, and improving animal compliance. With its excellent pharmacokinetic properties and broad-spectrum antibacterial activity, it has become a preferred drug for the prevention and treatment of bacterial respiratory diseases in livestock, providing strong support for animal health and the stability of modern animal husbandry production.

Hot Tags: tildipirosin, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, API Researching Only , Medetomidine HCl, procaine powder, sapropterin dihydrochloride powder, tetrahydrobiopterin synthesis, Xylazine hydrochloride